T. Rowe Price Associates’s SpringWorks Therapeutics SWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-69,269
| Closed | -$3.25M | – | 3123 |
|
|
2025
Q2 | $3.25M | Sell |
69,269
-2,513,463
| -97% | -$112M | ﹤0.01% | 1440 |
|
|
2025
Q1 | $114M | Sell |
2,582,732
-692,054
| -21% | -$31.9M | 0.01% | 533 |
|
|
2024
Q4 | $118M | Sell |
3,274,786
-241,632
| -7% | -$8.44M | 0.01% | 536 |
|
|
2024
Q3 | $113M | Sell |
3,516,418
-85,816
| -2% | -$3.21M | 0.01% | 542 |
|
|
2024
Q2 | $136M | Sell |
3,602,234
-508,228
| -12% | -$21.4M | 0.02% | 478 |
|
|
2024
Q1 | $202M | Buy |
4,110,462
+1,333,892
| +48% | +$61.7M | 0.02% | 418 |
|
|
2023
Q4 | $101M | Buy |
2,776,570
+1,221,056
| +78% | +$31.9M | 0.01% | 540 |
|
|
2023
Q3 | $36M | Buy |
1,555,514
+214,884
| +16% | +$5.88M | 0.01% | 776 |
|
|
2023
Q2 | $35.2M | Buy |
1,340,630
+1,067,203
| +390% | +$28M | ﹤0.01% | 804 |
|
|
2023
Q1 | $7.04M | Buy |
273,427
+34,774
| +15% | +$1.02M | ﹤0.01% | 1112 |
|
|
2022
Q4 | $6.21M | Sell |
238,653
-10,202
| -4% | -$251K | ﹤0.01% | 1142 |
|
|
2022
Q3 | $7.1M | Buy |
248,855
+7,412
| +3% | +$213K | ﹤0.01% | 1133 |
|
|
2022
Q2 | $5.94M | Sell |
241,443
-73,999
| -23% | -$2.71M | ﹤0.01% | 1400 |
|
|
2022
Q1 | $17.8M | Buy |
315,442
+3,401
| +1% | +$195K | ﹤0.01% | 1260 |
|
|
2021
Q4 | $19.3M | Buy |
312,041
+4,634
| +2% | +$307K | ﹤0.01% | 1290 |
|
|
2021
Q3 | $19.5M | Sell |
307,407
-1,530
| -0.5% | -$118K | ﹤0.01% | 1302 |
|
|
2021
Q2 | $25.5M | Sell |
308,937
-18,742
| -6% | -$1.42M | ﹤0.01% | 1236 |
|
|
2021
Q1 | $24.1M | Buy |
327,679
+1,499
| +0.5% | +$117K | ﹤0.01% | 1231 |
|
|
2020
Q4 | $23.7M | Buy |
+326,180
| New | +$21M | ﹤0.01% | 1180 |
|
Other funds holding SWTX
T. Rowe Price Associates's SWTX Position: Q3 2025 in Review
T. Rowe Price Associates sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 69,269 shares — an estimated $3.25M sold.
T. Rowe Price Associates first reported a position in SWTX in Q4 2020 and held it in 19 quarters. The position peaked at $202M in Q1 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.
- T. Rowe Price Associates reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
- T. Rowe Price Associates sold 69,269 SpringWorks Therapeutics shares in Q3 2025, an estimated $3.25M.
- T. Rowe Price Associates first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 19 quarters.
- T. Rowe Price Associates's SpringWorks Therapeutics position peaked at $202M in Q1 2024.
- 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.
Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.